跳至主要内容
临床试验/NCT01088594
NCT01088594已完成1 期

A Methodological Study To Evaluate The Effects of Single Oral Doses Of Pioglitazone 45 mg And Rosiglitazone 8 mg On Sodium Balance In Healthy Male Volunteers

Solvay Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2010年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
12
试验地点
1
主要终点
Time-course urinary sodium excretion calculated on the Day 1 of each study period

研究概览

简要总结

A single centre, open, randomized, placebo controlled, 3 period cross-over study to evaluate the effects of single oral doses of pioglitazone 45mg, rosiglitazone 8mg and placebo on urinary sodium excretion in 12 healthy male volunteers

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

1

Experimental

pioglitazone 45 mg

干预措施: pioglitazone/rosiglitazone/placebo (Drug)

1

Experimental

pioglitazone 45 mg

干预措施: rosiglitazone/pioglitazone/placebo (Drug)

1

Experimental

pioglitazone 45 mg

干预措施: placebo/pioglitazone/rosiglitazone (Drug)

1

Experimental

pioglitazone 45 mg

干预措施: pioglitazone/placebo/rosiglitazone (Drug)

1

Experimental

pioglitazone 45 mg

干预措施: rosiglitazone/placebo/pioglitazone (Drug)

1

Experimental

pioglitazone 45 mg

干预措施: placebo/rosiglitazone/pioglitazone (Drug)

2

Experimental

Rosiglitazone 8 mg

干预措施: pioglitazone/rosiglitazone/placebo (Drug)

2

Experimental

Rosiglitazone 8 mg

干预措施: rosiglitazone/pioglitazone/placebo (Drug)

2

Experimental

Rosiglitazone 8 mg

干预措施: placebo/pioglitazone/rosiglitazone (Drug)

2

Experimental

Rosiglitazone 8 mg

干预措施: pioglitazone/placebo/rosiglitazone (Drug)

2

Experimental

Rosiglitazone 8 mg

干预措施: rosiglitazone/placebo/pioglitazone (Drug)

2

Experimental

Rosiglitazone 8 mg

干预措施: placebo/rosiglitazone/pioglitazone (Drug)

3

Placebo Comparator

Placebo

干预措施: pioglitazone/rosiglitazone/placebo (Drug)

3

Placebo Comparator

Placebo

干预措施: rosiglitazone/pioglitazone/placebo (Drug)

3

Placebo Comparator

Placebo

干预措施: placebo/pioglitazone/rosiglitazone (Drug)

3

Placebo Comparator

Placebo

干预措施: pioglitazone/placebo/rosiglitazone (Drug)

3

Placebo Comparator

Placebo

干预措施: rosiglitazone/placebo/pioglitazone (Drug)

3

Placebo Comparator

Placebo

干预措施: placebo/rosiglitazone/pioglitazone (Drug)

结局指标

主要结局

Time-course urinary sodium excretion calculated on the Day 1 of each study period

时间窗: 0-6 hours

Time-course absolute urinary sodium excretion calculated on the Day 1 of each study period

时间窗: 0-6 hours

次要结局

  • Sodium clearance on Day 1 of each study period(0-6 hours)
  • Creatinine clearance calculated on Day 1 of each study period(0-6 hours)

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验